Therefore, it was found in a prospective study that combination of PSMA PET and multiparametric MRI provided a reliable TNM staging in patients with prostate cancer with a change in the therapeutic management for almost one third of the patients (75), PSMA PET being particularly interesting to delineate lymph node metastases (76). This evidence concerns the gene FOLH1 and Familial prostate cancer.